An integrative paradigm to impart quality to correlative science

por Kalos, Michael
Publicado 2010

Biomarkers in T cell therapy clinical trials

por Kalos, Michael
Publicado 2011

Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds

por Kalos, Michael
Publicado 2016

High-content molecular profiling of T-cell therapy in oncology

por Novosiadly, Ruslan, Kalos, Michael
Publicado 2016

Chimeric Antigen Receptor Therapy for B-cell Malignancies

por Porter, David L, Kalos, Michael, Zheng, Zhaohui, Levine, Bruce, June, Carl
Publicado 2011

Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?

por Bauml, Joshua, Chen, Lu, Chen, Jinbo, Boyer, Jean, Kalos, Michael, Li, Susan Q., DeMichele, Angela, Mao, Jun J.
Publicado 2015

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium

por Britten, Cedrik Michael, Janetzki, Sylvia, Ben-Porat, Leah, Clay, Timothy M., Kalos, Michael, Maecker, Holden, Odunsi, Kunle, Pride, Michael, Old, Lloyd, Hoos, Axel, Romero, Pedro
Publicado 2009

A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols

por Attig, Sebastian, Price, Leah, Janetzki, Sylvia, Kalos, Michael, Pride, Michael, McNeil, Lisa, Clay, Tim, Yuan, Jianda, Odunsi, Kunle, Hoos, Axel, Romero, Pedro, Britten, Cedrik M
Publicado 2011

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

por Janetzki, Sylvia, Panageas, Katherine S., Ben-Porat, Leah, Boyer, Jean, Britten, Cedrik M., Clay, Timothy M., Kalos, Michael, Maecker, Holden T., Romero, Pedro, Yuan, Jianda, Martin Kast, W., Hoos, Axel
Publicado 2007

Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint i...

por Schaer, David, Li, Yanxia, Castaneda, Stephen, Inigo, Ivan, Surguladze, David, Xu, Xiaohong, Nugent, Desiree, Murphy, Mary, Hall, Gerald, Benhadji, Karim, Guba, Susan, Li, Yiwen, Kalos, Michael, Driscoll, Kyla
Publicado 2015

CD8(+) T Cell Tolerance to a Tumor-associated Antigen Is Maintained at the Level of Expansion Rather than Effector Function

por Öhlén, Claes, Kalos, Michael, Cheng, Laurence E., Shur, Aaron C., Hong, Doley J., Carson, Bryan D., Kokot, Niels C.T., Lerner, Cara G., Sather, Blythe D., Huseby, Eric S., Greenberg, Philip D.
Publicado 2002

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

por Li, Yanxia, Amaladas, Nelusha, O’Mahony, Marguerita, Manro, Jason R., Inigo, Ivan, Li, Qi, Rasmussen, Erik R., Brahmachary, Manisha, Doman, Thompson N., Hall, Gerald, Kalos, Michael, Novosiadly, Ruslan, Puig, Oscar, Pytowski, Bronislaw, Schaer, David A.
Publicado 2022

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

por Li, Yiwen, Carpenito, Carmine, Wang, George, Surguladze, David, Forest, Amelie, Malabunga, Maria, Murphy, Mary, Zhang, Yiwei, Sonyi, Andreas, Chin, Darin, Burtrum, Douglas, Inigo, Ivan, Pennello, Anthony, Shen, Leyi, Malherbe, Laurent, Chen, Xinlei, Hall, Gerald, Haidar, Jaafar N., Ludwig, Dale L., Novosiadly, Ruslan D., Kalos, Michael
Publicado 2018

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combinat...

por Holmgaard, Rikke B., Schaer, David A., Li, Yanxia, Castaneda, Stephen P., Murphy, Mary Y., Xu, Xiaohong, Inigo, Ivan, Dobkin, Julie, Manro, Jason R., Iversen, Philip W., Surguladze, David, Hall, Gerald E., Novosiadly, Ruslan D., Benhadji, Karim A., Plowman, Gregory D., Kalos, Michael, Driscoll, Kyla E.
Publicado 2018

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

por Li, Yiwen, Carpenito, Carmine, Wang, George, Surguladze, David, Forest, Amelie, Malabunga, Maria, Murphy, Mary, Zhang, Yiwei, Sonyi, Andreas, Chin, Darin, Burtrum, Douglas, Inigo, Ivan, Pennello, Anthony, Shen, Leyi, Malherbe, Laurent, Chen, Xinlei, Hall, Gerald, Haidar, Jaafar N., Ludwig, Dale L., Novosiadly, Ruslan D., Kalos, Michael
Publicado 2018

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer

por Stroncek, David F, Berger, Carolina, Cheever, Martin A, Childs, Richard W, Dudley, Mark E, Flynn, Peter, Gattinoni, Luca, Heath, James R, Kalos, Michael, Marincola, Francesco M, Miller, Jeffrey S, Mostoslavsky, Gustavo, Powell, Daniel J, Rao, Mahendra, Restifo, Nicholas P, Rosenberg, Steven A, O'Shea, John, Melief, Cornelis JM
Publicado 2012

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors

por McCormack, Emmet, Adams, Katherine J., Hassan, Namir J., Kotian, Akhil, Lissin, Nikolai M., Sami, Malkit, Mujić, Maja, Osdal, Tereza, Gjertsen, Bjørn Tore, Baker, Deborah, Powlesland, Alex S., Aleksic, Milos, Vuidepot, Annelise, Morteau, Olivier, Sutton, Deborah H., June, Carl H., Kalos, Michael, Ashfield, Rebecca, Jakobsen, Bent K.
Publicado 2012

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

por Yingling, Jonathan M., McMillen, William T., Yan, Lei, Huang, Huocong, Sawyer, J. Scott, Graff, Jeremy, Clawson, David K., Britt, Karen S., Anderson, Bryan D., Beight, Douglas W., Desaiah, Durisala, Lahn, Michael M., Benhadji, Karim A., Lallena, Maria J., Holmgaard, Rikke B., Xu, Xiaohong, Zhang, Faming, Manro, Jason R., Iversen, Philip W., Iyer, Chandrasekar V., Brekken, Rolf A., Kalos, Michael D., Driscoll, Kyla E.
Publicado 2017

Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT

por Rapoport, Aaron P, Stadtmauer, Edward A, Vogl, Dan T, Weiss, Brendan, Binder-Scholl, Gwendolyn K, Smethurst, Dominic P, Finklestein, Jeffrey, Kulikovskaya, Irina, Gupta, Minnal, Brewer, Joanna E, Bennett, Alan D, Gerry, Andrew B, Pumphrey, Nick J, Tayton-Martin, Helen K, Ribeiro, Lilliam, Badros, Ashraf Z, Yanovich, Saul, Akpek, Gorgun, Kerr, Naseem, Philip, Sunita, Westphal, Sandra, Bruce, Levine L, Jakobsen, Bent K, June, Carl H, Kalos, Michael
Publicado 2013

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

por Kohrt, Holbrook E., Tumeh, Paul C., Benson, Don, Bhardwaj, Nina, Brody, Joshua, Formenti, Silvia, Fox, Bernard A., Galon, Jerome, June, Carl H., Kalos, Michael, Kirsch, Ilan, Kleen, Thomas, Kroemer, Guido, Lanier, Lewis, Levy, Ron, Lyerly, H. Kim, Maecker, Holden, Marabelle, Aurelien, Melenhorst, Jos, Miller, Jeffrey, Melero, Ignacio, Odunsi, Kunle, Palucka, Karolina, Peoples, George, Ribas, Antoni, Robins, Harlan, Robinson, William, Serafini, Tito, Sondel, Paul, Vivier, Eric, Weber, Jeff, Wolchok, Jedd, Zitvogel, Laurence, Disis, Mary L., Cheever, Martin A.
Publicado 2016